Benefits of Cabazitaxel in Advanced Stages of Prostate Cancer

Benefits of Cabazitaxel in Advanced Stages of Prostate Cancer
A recent study entitled “Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer” published in Clinical Cancer Research showed that cabazitaxel, a new member of the taxane family and FDA approved drug, may be more efficient for treating some prostate cancer patients, a hypothesis now being tested in clinical trials. In the United States, prostate cancer is the second most common type of cancer in men, with taxanes comprising the only class of chemotherapeutics available to treat this type of cancer. To improve the outcomes of patients with castration-resistant prostate cancer (CRPC) there is an urgent need for more effective therapies and approaches with specific treatments. For a long time, docetaxel has been the most effective chemotherapy for patients with prostate cancer that were non-responsive to hormone therapy. Cabazitaxel belongs to the second generation of drugs within the taxanes family and was only applied in patients that did not respond to hormone and docetaxel therapy. Study author Dr. Karen Knudsen explained in a news release that although both drugs belong to the taxanes family, their function is completely different. “It shows that we may not be taking full advantage of this next generation taxane in the clinic," said Dr. Knudsen. The team showed that cabazitaxel might be more efficient than docetaxel when used to treat hormone-resistant human prostate cancer cell lines and in earlier phases of treatment. They observed that the drugs had different modes of action: while cabazitaxel had a higher effect on cellular division and regulation of chromatin, docetaxel affected DNA transcription and repair. Moreover, researchers tested both drugs in parallel on slices of tumors collected from patients du
Subscribe or to access all post and page content.